8-K
Horizon Therapeutics Public Ltd Co 00-0000000 false 0001492426 0001492426 2020-08-03 2020-08-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2020

 

 

Horizon Therapeutics Public Limited Company

(Exact name of registrant as specified in its charter)

 

 

 

Ireland   001-35238   Not Applicable

(State or other jurisdiction

of incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: 011-353-1-772-2100

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Ordinary shares, nominal value $0.0001 per share   HZNP   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 2.02

Results of Operations and Financial Condition.

On August 5, 2020, Horizon Therapeutics plc issued a press release announcing its financial results for the second quarter ended June 30, 2020. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As Horizon continues to grow at a rapid pace, it is expanding its leadership structure to separate the geographic oversight of its commercial operations to prepare for long-term global expansion. As of August 3, 2020, Vikram Karnani now oversees international operations as executive vice president and president, International and Daniel A. Camardo now oversees U.S. operations as executive vice president and president, U.S.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

  

Description

99.1    Press Release of Horizon Therapeutics plc, dated August 5, 2020. 
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 5, 2020    

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

    By:  

/s/ Paul W. Hoelscher

      Paul W. Hoelscher
      Executive Vice President and Chief Financial Officer
EX-99.1

Exhibit 99.1

 

LOGO

 

Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results;

Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million;

Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance

— Record Second-Quarter 2020 Net Sales of $462.8 Million Increased 44 Percent;

Second-Quarter 2020 GAAP Net Loss of $80.0 Million; Adjusted EBITDA of $190.7 Million —

— Quarterly Orphan Segment Net Sales Increased 87 Percent to $379.3 Million;

Now Represents More Than 80 Percent of Total Company Net Sales —

— TEPEZZA (teprotumumab-trbw) Second-Quarter 2020 Net Sales of $165.9 Million Driven by

Strong Commercial Execution, Significantly Exceeding Expectations;

Increasing Full-Year 2020 Guidance to Greater Than $650 Million from Greater Than $200 Million —

— Increasing TEPEZZA Peak U.S. Annual Net Sales Estimate to

Greater Than $3 Billion from Greater Than $1 Billion —

— Increasing Full-Year 2020 Net Sales Guidance to $1.85 Billion to $1.90 Billion

Driven by Significantly Higher TEPEZZA Net Sales; Increasing Full-Year 2020 Adjusted EBITDA Guidance

to $725 Million to $775 Million —

— Announced Top-Line TEPEZZA Data that Underscore Its Efficacy in Longer Disease Duration,

Long-Term Durability and Potential for Retreatment —

— Anticipate Initiating TEPEZZA Chronic (Inactive) Thyroid Eye Disease (TED) Trial by Year-End 2020 —

— Reached Target Enrollment in KRYSTEXXA® MIRROR Immunomodulation

Randomized Controlled Trial (RCT) —

— Cash Position of $718.1 Million and Net Leverage of 0.9 Times as of June 30, 2020 —

DUBLIN Aug. 5, 2020 – Horizon Therapeutics plc (Nasdaq: HZNP) today announced record second-quarter 2020 financial results. The Company increased its full-year 2020 net sales and adjusted EBITDA guidance on continued strength of TEPEZZA. In addition to increasing TEPEZZA full-year 2020 net sales guidance, the Company also increased its peak U.S. annual net sales estimate for the medicine.

“Driving our record second-quarter performance was the continued tremendous patient and physician response to TEPEZZA, along with our outstanding commercial execution, making the TEPEZZA launch one of the most successful rare disease medicine launches ever, despite a challenging COVID-19 environment,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “With TEPEZZA results having once again dramatically exceeded expectations, we increased both our TEPEZZA and Company full-year net sales guidance, as well as increased our TEPEZZA peak U.S. annual net sales estimate. We also continued to advance our clinical programs and improve our capital structure during the quarter. With our strong track record of strategic execution and driving value for patients and shareholders alike, Horizon is well positioned for long-term growth and success.”

 

Horizon Therapeutics plc   1


LOGO

 

Financial Highlights

 

(in millions except for per share amounts and percentages)    Q2 20     Q2 19     %
Change
    YTD 20     YTD 19     %
Change
 

Net sales

   $  462.8     $  320.6       44     $  818.7     $  601.0       36  

Net loss

     (80.0     (5.1     NM       (93.6     (38.0     146  

Non-GAAP net income

     83.8       95.6       (12     167.0       149.6       12  

Adjusted EBITDA

     190.7       124.1       54       297.9       212.5       40  

Loss per share - diluted

     (0.42     (0.03     NM       (0.49     (0.21     133  

Non-GAAP earnings per share - diluted

     0.40       0.49       (18     0.80       0.80       —    

Second-Quarter and Recent Company Highlights

 

   

Strong Commercial Launch Drives Increase of TEPEZZA Peak U.S. Annual Net Sales Estimate: Today, the Company increased its peak U.S. annual net sales estimate for TEPEZZA to greater than $3 billion from the previous estimate of greater than $1 billion, as well as increased full-year 2020 net sales guidance to greater than $650 million from greater than $200 million. Several factors have contributed to the increased expectations, including the severity of TED, which is a motivating factor for patients seeking treatment; the Company’s market education efforts to increase awareness of TED, develop the market and assist with patient access; and a high volume of patient and physician interest driven by the Company’s commercial execution.

 

   

Announced Topline Data from TEPEZZA OPTIC-X Open-Label Extension Trial and OPTIC 48-Week Off-Treatment Follow-Up Period: In July 2020, the Company announced new topline results from its OPTIC-X open-label clinical trial, an extension trial of OPTIC, the TEPEZZA Phase 3 pivotal confirmatory clinical trial, as well as data from the OPTIC 48-week off-treatment follow-up period. OPTIC-X results demonstrate that 89 percent of patients who received placebo during OPTIC and then entered OPTIC-X and received TEPEZZA achieved the primary endpoint of 2 mm or more reduction in proptosis at Week 24. These patients had TED diagnosis for an average of one year compared with an average of six months in OPTIC. The results of the OPTIC 48-week off-treatment follow-up period demonstrated that the majority of TEPEZZA patients who were proptosis responders at Week 24 of OPTIC maintained their response at Week 72, nearly a year off treatment. For the small number of TEPEZZA patients who relapsed during the OPTIC follow-up period, the majority experienced improvements in proptosis with an additional course of TEPEZZA in OPTIC-X.

 

   

Reached Target Enrollment for KRYSTEXXA MIRROR RCT: In July 2020, the Company announced that the MIRROR RCT, the first randomized trial to evaluate the efficacy and safety of the concomitant use of KRYSTEXXA with methotrexate to increase the duration of response of KRYSTEXXA, reached its target enrollment of 135 patients. Preliminary results are expected in the first half of 2021.

 

Horizon Therapeutics plc   2


LOGO

 

   

New KRYSTEXXA Immunomodulation Data Presented: A series of data on KRYSTEXXA co-prescribed with commonly used immunomodulators, including methotrexate, leflunomide, mycophenolate mofetil and azathioprine, were presented virtually at the 2020 European League Against Rheumatism (EULAR) congress in June. The presentations showed response rates for KRYSTEXXA with immunomodulators ranging between 70 and 100 percent. The response rate of the KRYSTEXXA Phase 3 trials was 42 percent. The presentations added to the growing body of evidence supporting the immunomodulation treatment approach.

 

   

Expanded the Company’s Pipeline with Acquisition of Development-Stage Candidate HZN-825: On April 1, 2020, the Company completed the acquisition of Curzion Pharmaceuticals, Inc. and its lysophosphatidic acid 1 receptor (LPAR1) antagonist candidate (renamed HZN-825) for the treatment of diffuse cutaneous systemic sclerosis (dcSSc).

 

   

Permanent J-Code Issued for TEPEZZA: In July 2020, the Company announced that the U.S. Centers for Medicare and Medicaid Services (CMS) assigned a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) J-code (J3241) for TEPEZZA. The permanent J-code, which enables reimbursement in all outpatient treatment settings, is expected to go into effect on Oct. 1, 2020.

 

   

Acquired Certain Rights to Proceeds from Future Milestones and Royalties Related to TEPEZZA: In April 2020, in two separate transactions, the Company acquired the rights to proceeds from certain contingent future milestones and royalties related to TEPEZZA net sales in exchange for an aggregate payment of $110 million. These transactions relate to the rights to approximately 71 percent of the $225 million in milestone payments due upon achievement of certain TEPEZZA annual worldwide net sales thresholds and approximately 71 percent of the 3 percent royalty tied to the portion of TEPEZZA annual worldwide net sales exceeding $300 million.

 

   

Further Improved the Companys Capital Structure: On Aug. 3, 2020, the Company completed the extinguishment of all $400 million of its 2.50 percent exchangeable senior notes due 2022. Since the beginning of 2019, the Company has reduced its gross debt by approximately $1 billion, while maintaining a strong cash balance. In part as a result of the extinguishment, S&P revised its outlook on the Company to positive from stable.

 

   

Announced Expanded Commercial Leadership Structure: As Horizon continues to grow at a rapid pace, it is expanding its leadership structure to separate the geographic oversight of its commercial operations to prepare for long-term global expansion. Vikram Karnani will now oversee international operations as executive vice president and president, International and Daniel A. Camardo will now oversee U.S. operations as executive vice president and president, U.S.

 

   

Received Best Workplace Awards: In April 2020, Great Place to Work® and Fortune selected Horizon as one of the 2020 “Best Workplaces in Health Care and Biopharma” for the third consecutive year and Great Place to Work also named Horizon as the No. 1 “Best Workplace in Chicago” in the small and medium category.

 

Horizon Therapeutics plc   3


LOGO

 

Key Research and Development Programs

 

   

HZN-825 dcSSc Program: HZN-825 is the Company’s LPAR1 antagonist in development for the treatment of dcSSc, a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, with no FDA-approved treatment options. The Company expects to begin a Phase 2b pivotal trial in the first half of 2021.

 

   

TEPEZZA Trial in Chronic (Inactive) TED: The Company expects to initiate a trial of TEPEZZA in patients with chronic TED (previously referred to as inactive TED) by year-end 2020. In chronic TED, the disease is no longer progressive; however, significant disease manifestations such as proptosis (eye bulging) and diplopia (double vision) remain.

 

   

Potential TEPEZZA Subcutaneous Administration Program: The Company is planning to initiate a pharmacokinetic trial later this year to explore subcutaneous dosing of TEPEZZA, which is currently administered by infusion. The objective of the trial is to inform the potential for additional administration options for TEPEZZA, which could provide greater flexibility for patients and physicians.

 

   

TEPEZZA dcSSc Exploratory Trial: As part of its evaluation of additional indications for TEPEZZA, the Company is planning to initiate an exploratory trial in dcSSc by the end of 2020.

 

   

KRYSTEXXA MIRROR RCT: The Company is currently evaluating the efficacy and safety of the concomitant use of KRYSTEXXA with methotrexate to increase the complete response rate of KRYSTEXXA in the MIRROR placebo-controlled RCT. In July 2020, MIRROR RCT reached its target enrollment of 135 patients, and additional patients in screening will also randomize if eligible. The registrational trial is designed to enable the potential submission of results to the FDA to update the prescribing information. The MIRROR RCT follows the MIRROR open-label trial completed in 2019 that demonstrated a 79 percent complete response rate for patients using KRYSTEXXA with methotrexate, nearly double the 42 percent response rate in the KRYSTEXXA Phase 3 clinical program, which evaluated KRYSTEXXA alone. Methotrexate is the immunomodulator most used by rheumatologists and has been shown to reduce anti-drug antibody formation to biologic therapies when used in conjunction with these therapies.

 

   

KRYSTEXXA PROTECT Trial in Kidney Transplant Patients with Uncontrolled Gout: The Company has achieved more than 50 percent enrollment in its PROTECT open-label clinical trial, and expects to complete enrollment by the end of 2020. The trial is evaluating the effect of KRYSTEXXA on serum uric acid levels in kidney transplant patients with uncontrolled gout. Kidney transplant patients have more than a tenfold increase in the prevalence of gout when compared to the general population, and literature suggests that persistently high serum uric acid levels can be associated with organ rejection. Managing uncontrolled gout is one of the most common and significant unmet needs of kidney transplant patients.

 

Horizon Therapeutics plc   4


LOGO

 

   

KRYSTEXXA Shorter-Infusion Duration Trial: The Company expects to initiate an open-label trial by the end of 2020 to evaluate the impact of administering KRYSTEXXA over a significantly shorter infusion duration. Currently, KRYSTEXXA is infused over a two-hour or longer timeframe. A shorter infusion duration could meaningfully improve the experience and convenience for patients, physicians and sites of care.

Second-Quarter Financial Results

Note: For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release.

 

   

Net Sales: Second-quarter 2020 net sales were $462.8 million, an increase of 44 percent.

 

   

Gross Profit: Under U.S. GAAP, the second-quarter 2020 gross profit ratio was 73.7 percent compared to 72.2 percent in the second quarter of 2019. The non-GAAP gross profit ratio in the second quarter of 2020 was 88.4 percent compared to 90.9 percent in the second quarter of 2019.

 

   

Operating Expenses: Research and development (R&D) expenses were 17.5 percent of net sales and selling, general and administrative (SG&A) expenses were 48.0 percent of net sales. Non-GAAP R&D expenses were 6.1 percent of net sales, and non-GAAP SG&A expenses were 41.4 percent of net sales.

 

   

Income Tax Expense: In the second quarter of 2020, income tax expense on a GAAP and non-GAAP basis was $83.0 million and $93.6 million, respectively.

 

   

Net (Loss) Income: On a GAAP basis in the second quarter of 2020, net loss was $80.0 million. Second-quarter 2020 non-GAAP net income was $83.8 million.

 

   

Adjusted EBITDA: Second-quarter 2020 adjusted EBITDA was $190.7 million.

 

   

(Loss) Earnings per Share: On a GAAP basis diluted loss per share in the second quarter of 2020 and 2019 was $0.42 and $0.03, respectively. Non-GAAP diluted earnings per share in the second quarter of 2020 and 2019 was $0.40 and $0.49, respectively. Weighted average shares outstanding used for calculating GAAP and non-GAAP diluted earnings per share in the second quarter of 2020 were 192.7 million and 214.5 million, respectively.

Second-Quarter Segment Results

Management uses net sales and segment operating income to evaluate the performance of the Company’s two segments, the orphan segment and the inflammation segment. While segment operating income contains certain adjustments to the directly comparable GAAP figures in the Company’s consolidated financial results, it is considered to be prepared in accordance with GAAP for purposes of presenting the Company’s segment operating results.

 

Horizon Therapeutics plc   5


LOGO

 

Orphan Segment

 

(in millions except for percentages)    Q2 20      Q2 19      %
Change
    YTD 20      YTD 19      %
Change
 

TEPEZZA®

     165.9        —          NM       189.4        —          NM  

KRYSTEXXA®

     75.2        79.8        (6     168.5        132.1        28  

RAVICTI®

     65.6        50.4        30       126.7        100.3        26  

PROCYSBI®

     41.4        41.2        —         79.7        80.7        (1

ACTIMMUNE®

     28.3        29.3        (3     54.8        51.0        7  

BUPHENYL®

     2.8        2.3        20       5.2        5.2        —    

QUINSAIRTM

     0.1        0.2        (65     0.3        0.4        (1
  

 

 

    

 

 

      

 

 

    

 

 

    

Orphan Net Sales

   $  379.3      $  203.2        87     $  624.6      $  369.7        69  
  

 

 

    

 

 

      

 

 

    

 

 

    

Orphan Segment Operating Income

   $ 151.5      $ 63.7        138     $ 205.9      $ 100.4        105  

 

   

Second-quarter 2020 net sales of the orphan segment, the Company’s strategic growth segment, were $379.3 million, an increase of 87 percent over the prior year’s quarter, driven by the strong performance of TEPEZZA and RAVICTI. Second-quarter KRYSTEXXA net sales reflect the impact of COVID-19. The orphan segment represented 82 percent of total second-quarter net sales.

 

   

Second-quarter 2020 orphan segment operating income was $151.5 million, which includes significant investment spend associated with the commercial launch of TEPEZZA.

Inflammation Segment

 

(in millions except for percentages)    Q2 20      Q2 19      %
Change
    YTD 20      YTD 19      %
Change
 

PENNSAID 2%®

     35.0        51.5        (32     76.6        101.7        (25

DUEXIS®

     27.8        30.0        (8     59.1        59.5        (1

RAYOS®

     14.5        20.3        (29     32.7        39.7        (18

VIMOVO®(1)

     6.2        14.6        (57     25.7        28.6        (10

MIGERGOT®(2)

     —          1.0        NM       —          1.8        NM  
  

 

 

    

 

 

      

 

 

    

 

 

    

Inflammation Net Sales

   $  83.5      $  117.4        (29   $  194.1      $  231.3        (16
  

 

 

    

 

 

      

 

 

    

 

 

    

Inflammation Segment Operating Income

   $ 38.1      $ 60.5        (37   $ 90.0      $ 111.9        (20

 

  (1)

On Feb. 27, 2020, Dr. Reddy’s Laboratory initiated an at-risk launch of generic VIMOVO in the United States.

  (2)

In June 2019, the Company divested the rights to MIGERGOT.

 

   

Second-quarter 2020 net sales of the inflammation segment were $83.5 million, which reflects the impact of COVID-19. Inflammation segment operating income was $38.1 million.

 

Horizon Therapeutics plc   6


LOGO

 

Cash Flow Statement and Balance Sheet Highlights

 

   

On a GAAP basis, operating cash flow in the second quarter of 2020 was $99.6 million. Non-GAAP operating cash flow was $100.0 million.

 

   

The Company had cash and cash equivalents of $718.1 million as of June 30, 2020. This reflects $157.1 million in payments in the quarter related to the acquisition of HZN-825 and the two TEPEZZA royalty and milestone transactions.

 

   

As of June 30, 2020, the total principal amount of debt outstanding was $1.211 billion, which reflects the exchange of $207.0 million of the total $400.0 million of the Company’s 2.50 percent exchangeable senior notes due 2022 into ordinary shares by holders during the second quarter. As of June 30, 2020, net debt was $492.9 million and net-debt-to-last-12-months adjusted EBITDA leverage ratio was 0.9 times, compared to 1.1 times as of June 30, 2019.

 

   

As of Aug. 3, 2020, the Company’s $400 million of 2.50 percent exchangeable senior notes due 2022 were fully extinguished through $398.3 million of exchanges for ordinary shares and $1.7 million of cash redemptions. Following these extinguishments, the Company’s gross debt was $1.018 billion.

Revised 2020 Guidance

The Company now expects full-year 2020 net sales to range between $1.85 billion to $1.90 billion, an increase from the previous guidance range of $1.40 billion to $1.45 billion. The Company now expects TEPEZZA full-year 2020 net sales of greater than $650 million, compared to the previous guidance of greater than $200 million. Full-year 2020 adjusted EBITDA is now expected to range between $725 million and $775 million, an increase from the previous guidance range of $450 million to $500 million.

Webcast

At 8 a.m. EST / 1 p.m. IST today, the Company will host a live webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

 

Horizon Therapeutics plc   7


LOGO

 

Note Regarding Use of Non-GAAP Financial Measures

EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon as non-GAAP financial measures. Horizon provides certain other financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax rate, non-GAAP operating cash flow, net leverage ratio and net debt, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures as well as EBITDA exclude acquisition and/or divestiture-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, gain or loss from divestiture, gain or loss from sale of assets, upfront, progress and milestone payments related to license and collaboration agreements, litigation settlements, loss on debt extinguishment, costs of debt refinancing, drug manufacturing harmonization costs, restructuring and realignment costs, the income tax effect on pre-tax non-GAAP adjustments and other non-GAAP income tax adjustments, as well as non-cash items such as share-based compensation, depreciation and amortization, non-cash interest expense, long-lived asset impairment charges and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected 2020 financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company’s performance. For example, adjusted EBITDA is used by Horizon as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided a reconciliation of its full-year 2020 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon’s stock price, the variability associated with the size or timing of acquisitions/divestitures and other factors. These components of net income (loss) could significantly impact Horizon’s actual net income (loss).

 

Horizon Therapeutics plc   8


LOGO

 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to Horizon’s full-year 2020 net sales and adjusted EBITDA guidance; expected financial performance and operating results in future periods, including potential growth in net sales of certain of Horizon’s medicines; development plans; expected timing of clinical trials, studies and regulatory submissions; potential market opportunity for and benefits of Horizon’s medicines and medicine candidates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; impacts of the COVID-19 pandemic and actions taken to slow its spread, including impacts on net sales of Horizon’s medicines and potential delays in clinical trials; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon’s ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

Contacts:

 

Investors:    U.S. Media:
Tina Ventura    Geoff Curtis
Senior Vice President,    Executive Vice President,
Investor Relations    Corporate Affairs & Chief Communications Officer
investor-relations@horizontherapeutics.com    media@horizontherapeutics.com
Ruth Venning    Ireland Media:
Executive Director,    Ray Gordon
Investor Relations    Gordon MRM
investor-relations@horizontherapeutics.com    ray@gordonmrm.ie

 

Horizon Therapeutics plc   9


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2020     2019     2020     2019  

Net sales

   $  462,779     $  320,647     $  818,688     $  601,018  

Cost of goods sold

     121,515       89,163       218,931       177,305  
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     341,264       231,484       599,757       423,713  
  

 

 

   

 

 

   

 

 

   

 

 

 

OPERATING EXPENSES:

        

Research and development

     81,068       28,314       108,277       50,039  

Selling, general and administrative

     222,332       167,095       470,107       339,394  

Loss on sale of assets

     —         10,963       —         10,963  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     303,400       206,372       578,384       400,396  
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     37,864       25,112       21,373       23,317  
  

 

 

   

 

 

   

 

 

   

 

 

 

OTHER EXPENSE, NET:

        

Interest expense, net

     (18,571     (22,033     (35,915     (49,563

Loss on debt extinguishment

     (17,254     (11,878     (17,254     (17,464

Foreign exchange gain

     283       76       1,059       15  

Other income (expense), net

     632       (1,272     1,074       (1,083
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other expense, net

     (34,910     (35,107     (51,036     (68,095
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (Loss) before expense (benefit) for income taxes

     2,954       (9,995     (29,663     (44,778

Expense (benefit) for income taxes

     82,964       (4,875     63,938       (6,795
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (80,010   $ (5,120   $ (93,601   $ (37,983
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per ordinary share - basic and diluted

   $ (0.42   $ (0.03   $ (0.49   $ (0.21
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average ordinary shares outstanding - basic and diluted

     192,705,535       185,327,383       191,426,864       178,866,391  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc   10


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share data)

 

     As of  
     June 30,
2020
    December 31,
2019
 

ASSETS

  

CURRENT ASSETS:

    

Cash and cash equivalents

   $ 718,062     $  1,076,287  

Restricted cash

     3,625       3,752  

Accounts receivable, net

     543,755       408,685  

Inventories, net

     66,099       53,802  

Prepaid expenses and other current assets

     157,548       143,577  
  

 

 

   

 

 

 

Total current assets

     1,489,089       1,686,103  
  

 

 

   

 

 

 

Property and equipment, net

     138,801       30,159  

Developed technology and other intangible assets, net

     1,891,100       1,702,628  

Goodwill

     413,669       413,669  

Deferred tax assets, net

     564,643       555,165  

Other assets

     40,889       48,310  
  

 

 

   

 

 

 

Total assets

   $  4,538,191     $ 4,436,034  
  

 

 

   

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

    

CURRENT LIABILITIES:

    

Exchangeable Senior Notes–current

   $ 174,504     $ —    

Accounts payable

     106,015       21,514  

Accrued expenses

     415,545       235,234  

Accrued trade discounts and rebates

     288,592       466,421  
  

 

 

   

 

 

 

Total current liabilities

     984,656       723,169  
  

 

 

   

 

 

 

LONG-TERM LIABILITIES:

    

Exchangeable Senior Notes, net

     —         351,533  

Long-term debt, net

     1,002,318       1,001,308  

Deferred tax liabilities, net

     99,164       94,247  

Other long-term liabilities

     90,201       80,328  
  

 

 

   

 

 

 

Total long-term liabilities

     1,191,683       1,527,416  
  

 

 

   

 

 

 

COMMITMENTS AND CONTINGENCIES

    

SHAREHOLDERS’ EQUITY:

    

Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2020 and December 31, 2019; 199,991,807 and 188,402,040 shares issued at June 30, 2020 and December 31, 2019, respectively, and 199,607,441 and 188,017,674 shares outstanding at June 30, 2020 and December 31, 2019, respectively

     20       19  

Treasury stock, 384,366 ordinary shares at June 30, 2020 and December 31, 2019

     (4,585     (4,585

Additional paid-in capital

     3,067,586       2,797,602  

Accumulated other comprehensive loss

     (1,886     (1,905

Accumulated deficit

     (699,283     (605,682
  

 

 

   

 

 

 

Total shareholders’ equity

     2,361,852       2,185,449  
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

   $ 4,538,191     $ 4,436,034  
  

 

 

   

 

 

 

 

Horizon Therapeutics plc   11


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

     Three Months Ended
June 30,
    Six Months Ended June 30,  
     2020     2019     2020     2019  

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net loss

   $  (80,010   $ (5,120   $ (93,601   $  (37,983

Adjustments to reconcile net loss to net cash provided by operating activities:

        

Depreciation and amortization expense

     73,655       59,126       139,396       118,017  

Equity-settled share-based compensation

     27,057       21,367       83,478       48,915  

Acquired in-process research and development expense

     47,517       —         47,517       —    

Loss on debt extinguishment

     17,254       11,878       17,254       17,464  

Amortization of debt discount and deferred financing costs

     5,248       5,771       10,817       11,622  

Loss on sale of assets

     —         10,963       —         10,963  

Deferred income taxes

     (2,479     (2,759     (4,561     (1,257

Foreign exchange and other adjustments

     851       84       661       493  

Changes in operating assets and liabilities:

        

Accounts receivable

     (118,256     9,019       (135,125     69,787  

Inventories

     2,101       343       (12,343     (504

Prepaid expenses and other current assets

     4,543       (17,807     (20,410     (17,696

Accounts payable

     55,004       5,138       83,555       11,554  

Accrued trade discounts and rebates

     (47,781     (8,247     (177,721     (59,151

Accrued expenses

     109,592       (6,736     81,505       (28,071

Deferred revenues

     —         2,477       —         2,410  

Other non-current assets and liabilities

     5,305       5,770       16,586       873  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by operating activities

     99,601       91,267       37,008       147,436  
  

 

 

   

 

 

   

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Proceeds from sale of assets

     —         6,000       —         6,000  

Payments for acquisitions

     (157,105     —         (262,305     —    

Change in escrow deposit for property purchase

     —         —         6,000       —    

Purchases of property and equipment

     (966     (5,009     (119,970     (6,858
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by investing activities

     (158,071     991       (376,275     (858
  

 

 

   

 

 

   

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

        

Repayment of senior notes

     —         (258,282     —         (258,282

Net proceeds from the issuance of ordinary shares

     —         (957     —         326,793  

Repayment of term loans

     —         (518,026     —         (818,026

Net proceeds from term loans

     —         517,378       —         517,378  

Proceeds from the issuance of ordinary shares in conjunction with ESPP program

     7,979       5,465       7,979       5,465  

Proceeds from the issuance of ordinary shares in connection with stock option exercises

     18,837       1,987       25,887       12,029  

Payment of employee withholding taxes relating to share-based awards

     (6,345     (7,203     (53,009     (24,374
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     20,471       (259,638     (19,143     (239,017
  

 

 

   

 

 

   

 

 

   

 

 

 

Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

     1,424       576       58       58  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net decrease in cash, cash equivalents and restricted cash

     (36,575     (166,804     (358,352     (92,381

Cash, cash equivalents and restricted cash, beginning of the period(1)

     758,262       1,036,540       1,080,039       962,117  
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash, cash equivalents and restricted cash, end of the period(1)

   $ 721,687     $ 869,736     $ 721,687     $ 869,736  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(1)

Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet.

 

Horizon Therapeutics plc   12


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Net Income and Earnings Per Share (Unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2020     2019     2020     2019  

GAAP net loss

   $ (80,010   $ (5,120   $ (93,601   $ (37,983

Non-GAAP adjustments:

        

Acquisition/divestiture-related costs

     47,103       1,200       47,097       2,546  

Restructuring and realignment costs

     —         13       —         33  

Amortization and step-up:

        

Intangible amortization expense

     66,749       57,683       125,324       115,100  

Inventory step-up expense

     —         (25     —         90  

Amortization of debt discount and deferred financing costs

     5,248       5,710       10,817       11,622  

Impairment of long-lived assets

     1,072       —         1,072       —    

Loss on sale of assets

     —         10,963       —         10,963  

Share-based compensation

     27,057       21,367       83,478       48,915  

Depreciation

     6,907       1,443       14,072       2,916  

Litigation settlements

     —         1,000       —         1,000  

Upfront, progress and milestone payments related to license and collaboration agreements

     3,000       4,000       3,000       6,000  

Fees related to refinancing activities

     —         1,033       54       1,175  

Loss on debt extinguishment

     17,254       11,878       17,254       17,464  

Drug substance harmonization costs

     —         234       290       314  

Charges relating to discontinuation of Friedreich’s ataxia program

     —         1,300       —         1,221  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total of pre-tax non-GAAP adjustments

     174,390       117,799       302,458       219,359  

Income tax effect of pre-tax non-GAAP adjustments

     (25,797     (15,621     (57,059     (30,372

Other non-GAAP income tax adjustments

     15,210       (1,452     15,210       (1,452
  

 

 

   

 

 

   

 

 

   

 

 

 

Total of non-GAAP adjustments

     163,803       100,726       260,609       187,535  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Net Income

   $ 83,793     $ 95,606     $ 167,008     $ 149,552  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Earnings Per Share:

        

Weighted average ordinary shares - Basic

     192,705,535       185,327,383       191,426,864       178,866,391  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Earnings Per Share - Basic:

        

GAAP loss per share - Basic

   $ (0.42   $ (0.03   $ (0.49   $ (0.21

Non-GAAP adjustments

     0.85       0.55       1.36       1.05  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP earnings per share - Basic

   $ 0.43     $ 0.52     $ 0.87     $ 0.84  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Net Income

   $ 83,793     $ 95,606     $ 167,008     $ 149,552  

Effect of assumed exchange of Exchangeable Senior Notes, net of tax

     1,692       —         3,567       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Numerator - non-GAAP Net Income

   $ 85,485     $ 95,606     $ 170,575     $ 149,552  
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average ordinary shares - Diluted

        

Weighted average ordinary shares - Basic

     192,705,535       185,327,383       191,426,864       178,866,391  

Ordinary share equivalents

     21,838,670       7,897,507       22,084,476       7,658,133  
  

 

 

   

 

 

   

 

 

   

 

 

 

Denominator - weighted average ordinary shares – Diluted

     214,544,205       193,224,890       213,511,340       186,524,524  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Earnings Per Share - Diluted

        

GAAP loss per share - Diluted

     (0.42     (0.03     (0.49     (0.21

Non-GAAP adjustments

     0.85       0.55       1.36       1.05  

Diluted earnings per share effect of ordinary share equivalents

     (0.03     (0.03     (0.07     (0.04
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP earnings per share - Diluted

   $ 0.40     $ 0.49     $ 0.80     $ 0.80  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc   13


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

EBITDA (Unaudited)

(in thousands)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2020     2019     2020     2019  

GAAP net loss

   $  (80,010   $ (5,120   $  (93,601   $  (37,983

Depreciation

     6,907       1,443       14,072       2,916  

Amortization and step-up:

        

Intangible amortization expense

     66,749       57,683       125,324       115,100  

Inventory step-up expense

     —         (25     —         90  

Interest expense, net (including amortization of debt discount and deferred financing costs)

     18,571       22,033       35,915       49,563  

Expense (benefit) for income taxes

     82,964       (4,875     63,938       (6,795
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA

   $ 95,181     $ 71,139     $  145,648     $ 122,891  
  

 

 

   

 

 

   

 

 

   

 

 

 

Other non-GAAP adjustments:

        

Acquisition/divestiture-related costs

     47,103       1,200       47,097       2,546  

Restructuring and realignment costs

     —         13       —         33  

Impairment of long-lived assets

     1,072       —         1,072       —    

Loss on sale of assets

     —         10,963       —         10,963  

Share-based compensation

     27,057       21,367       83,478       48,915  

Litigation settlements

     —         1,000       —         1,000  

Upfront, progress and milestone payments related to license and collaboration agreements

     3,000       4,000       3,000       6,000  

Fees related to refinancing activities

     —         1,033       54       1,175  

Loss on debt extinguishment

     17,254       11,878       17,254       17,464  

Drug substance harmonization costs

     —         234       290       314  

Charges relating to discontinuation of Friedreich’s ataxia program

     —         1,300       —         1,221  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total of other non-GAAP adjustments

     95,486       52,988       152,245       89,631  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA

   $  190,667     $  124,127     $ 297,893     $  212,522  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc   14


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Operating Income (Unaudited)

(in thousands)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2020      2019     2020      2019  

GAAP operating income

   $ 37,864      $ 25,112     $ 21,373      $ 23,317  

Non-GAAP adjustments:

          

Acquisition/divestiture-related costs

     46,988        73       47,272        1,275  

Restructuring and realignment costs

     —          13       —          33  

Amortization and step-up:

          

Intangible amortization expense

     66,749        57,683       125,324        115,100  

Inventory step-up expense

     —          (25     —          90  

Impairment of long-lived assets

     1,072        —         1,072        —    

Loss on sale of assets

     —          10,963       —          10,963  

Share-based compensation

     27,057        21,367       83,478        48,915  

Depreciation

     6,907        1,443       14,072        2,916  

Litigation settlements

     —          1,000       —          1,000  

Upfront, progress and milestone payments related to license and collaboration agreements

     3,000        4,000       3,000        6,000  

Fees related to refinancing activities

     —          1,033       54        1,175  

Drug substance harmonization costs

     —          234       290        314  

Charges relating to discontinuation of Friedreich’s ataxia program

     —          1,300       —          1,221  
  

 

 

    

 

 

   

 

 

    

 

 

 

Total of non-GAAP adjustments

     151,773        99,084       274,562        189,002  
  

 

 

    

 

 

   

 

 

    

 

 

 

Non-GAAP operating income

   $  189,637      $  124,196     $  295,935      $  212,319  
  

 

 

    

 

 

   

 

 

    

 

 

 

Orphan segment operating income

     151,541        63,696       205,897        100,400  

Inflammation segment operating income

     38,096        60,500       90,038        111,919  
  

 

 

    

 

 

   

 

 

    

 

 

 

Total segment operating income

   $ 189,637      $ 124,196     $ 295,935      $ 212,319  

Foreign exchange gain

     283        76       1,059        15  

Other income (expense), net

     747        (145     899        188  
  

 

 

    

 

 

   

 

 

    

 

 

 

Adjusted EBITDA

   $ 190,667      $ 124,127     $ 297,893      $ 212,522  
  

 

 

    

 

 

   

 

 

    

 

 

 

 

Horizon Therapeutics plc   15


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Gross Profit and Operating Cash Flow (Unaudited)

(in thousands, except percentages)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2020     2019     2020     2019  

Non-GAAP Gross Profit:

        

GAAP gross profit

   $  341,264     $  231,484     $  599,757     $  423,713  

Non-GAAP gross profit adjustments:

        

Acquisition/divestiture-related costs

     —         —         —         1,114  

Intangible amortization expense

     66,547       57,481       124,921       114,699  

Inventory step-up expense

     —         (25     —         90  

Share-based compensation

     1,288       951       3,977       1,990  

Depreciation

     90       158       418       317  

Drug substance harmonization costs

     —         234       290       314  

Charges relating to discontinuation of Friedreich’s ataxia program

     —         1,300       —         1,221  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total of Non-GAAP adjustments

     67,925       60,099       129,606       119,745  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP gross profit

   $ 409,189     $ 291,583     $ 729,363     $ 543,458  
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP gross profit %

     73.7     72.2     73.3     70.5

Non-GAAP gross profit %

     88.4     90.9     89.1     90.4

GAAP cash provided by operating activities

   $ 99,601     $ 91,267     $ 37,008     $ 147,436  

Cash payments for acquisition/divestiture-related costs

     —         142       (17     495  

Cash payments for restructuring and realignment costs

     94       839       189       2,882  

Cash payments for upfront, progress and milestone payments related to license and collaboration agreement

     —         —         —         2,000  

Cash payments drug substance harmonization costs

     290       25       290       672  

Cash payments for discontinuation of Friedreich’s ataxia program

     —         1,659       —         2,589  

Cash payments relating to refinancing activities

     —         1,797       73       1,806  
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP operating cash flow

   $ 99,985     $ 95,729     $ 37,543     $ 157,880  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc   16


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

EBITDA (Unaudited) - 2019

(in thousands)

 

     Twelve Months
Ended December 31,
 
     2019  

GAAP net income

   $ 573,020  

Depreciation

     6,733  

Amortization and step-up:

  

Intangible amortization expense

     230,424  

Inventory step-up expense

     89  

Interest expense, net (including amortization of debt discount and deferred financing costs)

     87,089  

Benefit for income taxes

     (593,244
  

 

 

 

EBITDA

   $ 304,111  
  

 

 

 

Other non-GAAP adjustments:

  

Acquisition/divestiture-related costs

     3,556  

Restructuring and realignment costs

     237  

Share-based compensation

     91,215  

Litigation settlements

     1,000  

Upfront, progress and milestone payments related to license and collaboration agreements

     9,073  

Fees related to refinancing activities

     2,292  

Loss on debt extinguishment

     58,835  

Drug substance harmonization costs

     457  

Charges relating to discontinuation of Friedreich’s ataxia program

     1,076  

Gain on sale of assets

     10,963  
  

 

 

 

Total of other non-GAAP adjustments

     178,704  
  

 

 

 

Adjusted EBITDA

   $ 482,815  
  

 

 

 

 

Horizon Therapeutics plc   17


LOGO

 

Horizon Therapeutics plc

Net Debt Reconciliation (Unaudited)

(in thousands)

 

     As of  
     June 30,
2020
     December 31,
2019
     June 30,
2019
 

Long-term debt, net

   $  1,002,318      $  1,001,308      $  1,025,096  

Exchangeable Senior Notes, current (1)

     174,504        —          —    

Exchangeable Senior Notes, net

     —          351,533        341,682  
  

 

 

    

 

 

    

 

 

 

Total Debt

     1,176,822        1,352,841        1,366,778  

Debt discount

     29,226        59,922        70,754  

Deferred financing fees

     4,934        5,263        5,494  
  

 

 

    

 

 

    

 

 

 

Total Principal Amount of Debt

     1,210,982        1,418,026        1,443,026  

Less: cash and cash equivalents

     718,062        1,076,287        865,997  
  

 

 

    

 

 

    

 

 

 

Net Debt

   $ 492,920      $ 341,739      $ 577,029  
  

 

 

    

 

 

    

 

 

 

 

(1)

On June 3, 2020, the Company issued a notice of redemption for all of the outstanding Exchangeable Senior Notes. During the three months ended June 30, 2020, the Company issued an aggregate of 7,225,368 of its ordinary shares to noteholders as a result of exchanges of $207.0 million in aggregate principal amount of Exchangeable Senior Notes. As of June 30, 2020, an aggregate principal amount of $193.0 million of Exchangeable Senior Notes were outstanding, which was partially offset by $18.5 million of unamortized debt discount on the consolidated balance sheet.

 

Horizon Therapeutics plc   18


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Tax Rate Reconciliation (Unaudited)

(in millions, except percentages and per share amounts)

 

     Q2 2020  
     Pre-tax Net
(Loss) Income
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income
(Loss)
    Diluted Earnings
(Loss) Per Share
 

As reported - GAAP

   $ 3.0     $ 83.0       NM     $  (80.0   $  (0.42

Non-GAAP adjustments

     174.4       10.6         148.6    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $  177.3     $ 93.6       52.8   $ 83.8     $ 0.40  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     Q2 2019  
     Pre-tax Net
(Loss) Income
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income
(Loss)
    Diluted Earnings
(Loss) Per Share
 

As reported - GAAP

   $  (10.0   $ (4.9     48.8   $ (5.1   $  (0.03

Non-GAAP adjustments

     117.8       17.1         100.7    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ 107.8     $ 12.2       11.3   $ 95.6     $ 0.49  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     YTD 2020  
     Pre-tax Net
(Loss) Income
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income
(Loss)
    Diluted Earnings
(Loss) Per Share
 

As reported - GAAP

   $  (29.7   $ 63.9       NM     $  (93.6   $  (0.49

Non-GAAP adjustments

     302.5       41.8         245.4    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ 272.8     $  105.8       39.0   $  167.0     $ 0.80  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     YTD 2019  
     Pre-tax Net
(Loss) Income
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income
(Loss)
    Diluted Earnings
(Loss) Per Share
 

As reported - GAAP

   $  (44.8   $ (6.8     15.2   $  (38.0   $  (0.21

Non-GAAP adjustments

     219.4       31.8         187.5    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ 174.6     $ 25.0       14.3   $ 149.5     $ 0.80  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc   19


LOGO

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2020

(Unaudited)

 

     COGS     Research &
Development
    Selling,
General &
Administrative
    Loss on Debt
Extinguishment
    Interest
Expense
    Other
Expense
     Income
Tax Benefit
(Expense)
 

GAAP as reported

   $  (121,515   $  (81,068   $  (222,332   $  (17,254   $  (18,571   $  632      $  (82,964

Non-GAAP Adjustments (in thousands):

               

Acquisition/divestiture-related costs(1)

     —         47,328       (340     —         —         115        —    

Amortization and step-up:

               

Intangible amortization expense(2)

     66,547       —         202       —         —         —          —    

Amortization of debt discount and deferred financing costs(3)

     —         —         —         —         5,248       —          —    

Impairment of long lived assets(4)

     —         —         1,072       —         —         —          —    

Share-based compensation(5)

     1,288       2,552       23,217       —         —         —          —    

Depreciation(6)

     90       18       6,799       —         —         —          —    

Upfront, progress and milestone payments related to license and collaboration agreements(7)

     —         3,000       —         —         —         —          —    

Loss on debt extinguishment(8)

     —         —         —         17,254       —         —          —    

Income tax effect on pre-tax non-GAAP adjustments(9)

     —         —         —         —         —         —          (25,797

Other non-GAAP income tax adjustments(10)

     —         —         —         —         —         —          15,210  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Total of non-GAAP adjustments

     67,925       52,898       30,950       17,254       5,248       115        (10,587
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Non-GAAP

   $ (53,590   $  (28,170   $  (191,382   $ —       $  (13,323   $ 747      $  (93,551
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2019

(Unaudited)

 

     COGS     Research &
Development
    Selling,
General &
Administrative
    Loss/(Gain)
on Sale
of Assets
    Loss on Debt
Extinguishment
    Interest
Expense
    Other
Income,
net
    Income
Tax Benefit
(Expense)
 

GAAP as reported

   $  (89,163   $  (28,314   $  (167,095   $  (10,963   $  (11,878   $  (22,033   $  (1,272   $  4,875  

Non-GAAP Adjustments (in thousands):

                

Acquisition/divestiture-related costs(1)

     —         —         73       —         —         —         1,127       —    

Restructuring and realignment costs(11)

     —         —         13       —         —         —         —         —    

Amortization and step-up:

                

Intangible amortization expense(2)

     57,481       —         202       —         —         —         —         —    

Inventory step-up expense

     (25     —         —         —         —         —         —         —    

Amortization of debt discount and deferred financing costs(3)

     —         —         —         —         —         5,710       —         —    

Loss on sale of assets(12)

     —         —         —         10,963       —         —         —         —    

Share-based compensation(5)

     951       2,343       18,073       —         —         —         —         —    

Depreciation(6)

     158       —         1,285       —         —         —         —         —    

Litigation settlements(13)

     —         —         1,000       —         —         —         —         —    

Upfront, progress and milestone payments related to license and collaboration agreements(7)

     —         4,000       —         —         —         —         —         —    

Loss on debt extinguishment(8)

     —         —         —         —         11,878       —         —         —    

Fees related to refinancing activities (14)

     —         —         1,033       —         —         —         —         —    

Drug substance harmonization costs(15)

     234       —         —         —         —         —         —         —    

Charges relating to discontinuation of Friedreich’s ataxia program(16)

     1,300       —         —         —         —         —         —         —    

Income tax effect on pre-tax non-GAAP adjustments(9)

     —         —         —         —         —         —         —         (15,621

Other non-GAAP income tax adjustments(10)

     —         —         —         —         —         —         —         (1,452
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total of non-GAAP adjustments

     60,099       6,343       21,679       10,963       11,878       5,710       1,127       (17,073
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $  (29,064   $  (21,971   $  (145,416   $ —       $ —       $  (16,323   $  (145   $  (12,198
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc   20


LOGO

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Six Months Ended June 30, 2020 (Unaudited)

(in thousands)

 

     COGS     Research &
Development
    Selling,
General &
Administrative
    Interest
Expense
    Other
Expense
    Loss on Debt
Extinguishment
    Income Tax
Benefit
(Expense)
 

GAAP as reported

   $  (218,931   $  (108,277   $  (470,107   $  (35,915   $  1,074     $  (17,254   $  (63,938 )

Non-GAAP Adjustments (in thousands):

              

Acquisition/divestiture-related costs(1)

     —         47,328       (56     —         (175     —         —    

Amortization and step-up:

              

Intangible amortization expense(2)

     124,921       —         403       —         —         —         —    

Amortization of debt discount and deferred financing costs(3)

     —         —         —         10,817       —         —         —    

Impairment of long lived assets(4)

     —         —         1,072       —         —         —         —    

Share-based compensation(5)

     3,977       8,928       70,573       —         —         —         —    

Depreciation(6)

     418       43       13,611       —         —         —         —    

Upfront, progress and milestone payments related to license and collaboration agreements(7)

     —         3,000       —         —         —         —         —    

Fees related to refinancing activities (14)

     —         —         54       —         —         —         —    

Loss on debt extinguishment(8)

     —         —         —         —         —         17,254       —    

Drug substance harmonization costs(15)

     290       —         —         —         —         —         —    

Income tax effect on pre-tax non-GAAP adjustments(9)

     —         —         —         —         —         —         (57,059

Other non-GAAP income tax adjustments(10)

     —         —         —         —         —         —         15,210  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total of non-GAAP adjustments

     129,606       59,299       85,657       10,817       (175     17,254       (41,849
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $  (89,325   $  (48,978   $  (384,450   $  (25,098   $ 899     $ —       $  (105,787
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Six Months Ended June 30, 2019

(Unaudited)

 

     COGS     Research &
Development
    Selling,
General &
Administrative
    Loss on Debt
Extinguishment
    Loss/(Gain)
on Sale of
Assets
    Interest
Expense
    Other
Income
    Income
Tax Benefit
(Expense)
 

GAAP as reported

   $  (177,305   $  (50,039   $  (339,394   $  (17,464   $  (10,963   $  (49,563     (1,083 )   $ 6,795  

Non-GAAP Adjustments (in thousands):

                

Acquisition/divestiture-related costs(1)

     1,114       —         164       —         —         —         1,268       —    

Restructuring and realignment costs(11)

     —         —         33       —         —         —         —         —    

Amortization and step-up:

                

Intangible amortization expense(2)

     114,699       —         401       —         —         —         —         —    

Inventory step-up expense

     90       —         —         —         —         —         —         —    

Amortization of debt discount and deferred financing costs(3)

     —         —         —         —         —         11,622       —         —    

Impairment of long lived assets(4)

     —         —         —         —         —         —         —         —    

Loss on sale of assets(12)

     —         —         —         —         10,963       —         —         —    

Share-based compensation(5)

     1,990       4,979       41,946       —         —         —         —         —    

Depreciation(6)

     317       —         2,599       —         —         —         —         —    

Litigation settlements(13)

     —         —         1,000       —         —         —         —         —    

Upfront, progress and milestone payments related to license and collaboration agreements(7)

     —         6,000       —         —         —         —         —         —    

Fees related to refinancing activities (14)

     —         —         1,175       —         —         —         —         —    

Loss on debt extinguishment(8)

     —         —         —         17,464       —         —         —         —    

Drug substance harmonization costs(15)

     314       —         —         —         —         —         —         —    

Charges relating to discontinuation of Friedreich’s ataxia program(16)

     1,221       —         —         —         —         —         —         —    

Income tax effect on pre-tax non-GAAP adjustments(9)

     —         —         —         —         —         —         —         (30,372

Other non-GAAP income tax adjustments(10)

     —         —         —         —         —         —         —         (1,452
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total of non-GAAP adjustments

     119,745       10,979       47,318       17,464       10,963       11,622       1,268       (31,824
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ (57,560   $  (39,060)     $  (292,076   $ —       $ —       $  (37,941   $ 185     $  (25,029
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc   21


LOGO

 

NOTES FOR CERTAIN INCOME STATEMENT LINE ITEMS - NON-GAAP

 

1.

Represents expenses, including legal and consulting fees, incurred in connection with our acquisitions and divestitures. Costs recovered from subleases of acquired facilities and reimbursed expenses incurred under transition arrangements for divestitures are also reflected in this line item. In addition, the three and six months ended June 30, 2020 amounts include the Curzion acquisition payment of $45.0 million, which was recorded as a research and development expense.

 

2.

Intangible amortization expenses are associated with our intellectual property rights, developed technology and customer relationships related to TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, RAYOS, PENNSAID 2%, VIMOVO and MIGERGOT.

 

3.

Represents amortization of debt discount and deferred financing costs associated with our debt.

 

4.

During the three and six months ended June 30, 2020, we recorded an impairment charge of $1.1 million related to the Novato, California office lease, which was obtained through an acquisition.

 

5.

Represents share-based compensation expense associated with our stock option, restricted stock unit and performance stock unit grants to our employees and non-employee directors, and our employee share purchase plan.

 

6.

Represents depreciation expense related to our property, equipment, software and leasehold improvements.

 

7.

During the six months ended June 30, 2020, we recognized a $3.0 million progress payment in relation to the collaboration agreement with HemoShear Therapeutics, LLC, or HemoShear, which was subsequently paid in July 2020. During the six months ended June 30, 2019, we recorded an upfront cash payment of $2.0 million and a $4.0 million progress payment in relation to the collaboration agreement with HemoShear.

 

8.

During the six months ended June 30, 2020, we recorded a loss on debt extinguishment of $17.3 million in the condensed consolidated statements of comprehensive loss, which reflects the partial redemption of our Exchangeable Senior Notes. During the six months ended June 30, 2019, we recorded a loss on debt extinguishment of $17.5 million in the condensed consolidated statements of comprehensive loss, which reflected the write-off of the deferred financing fees and debt discount fees related to the prepayment of $250.0 million of 2023 Senior Notes and term loan repayment of $300.0 million.

 

9.

Income tax adjustments on pre-tax non-GAAP adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the statutory income tax rate of the applicable jurisdictions for each non-GAAP adjustment.

 

Horizon Therapeutics plc   22


LOGO

 

10.

During the three months ended June 30, 2020, following the publication by the U.S. Treasury of Final Regulations for Section 267A (commonly referred to as the “Anti-Hybrid Rules”) on April 8, 2020, we recorded a write off of a deferred tax asset related to certain interest expense accrued to a foreign related party during the year ended December 31, 2019 and recognized a corresponding one-time tax provision, resulting in a non-GAAP tax adjustment of $15.2 million. During the three months ended June 30, 2019, we released a reserve related to an uncertain tax position in connection with an acquisition resulting in a non-GAAP tax adjustment of $1.5 million.

 

11.

Represents expenses, including severance costs and consulting fees, related to restructuring and realignment activities.

 

12.

During the six months ended June 30, 2019, we recorded a loss of $11.0 million on the sale of our rights to MIGERGOT.

 

13.

The Company recorded $1.0 million of expense during the three months ended June 30, 2019, for litigation settlements.

 

14.

Represents arrangement and other fees relating to our refinancing activities.

 

15.

During the year ended December 31, 2016, we entered into a definitive agreement to acquire certain rights to interferon gamma-1b, marketed as IMUKIN in an estimated thirty countries primarily in Europe and the Middle East, or the IMUKIN purchase agreement. We already owned the rights to interferon gamma-1b marketed as ACTIMMUNE in the United States, Canada and Japan. In connection with the IMUKIN purchase agreement, we also committed to pay our contract manufacturer certain amounts related to the harmonization of the manufacturing processes for ACTIMMUNE and IMUKIN drug substance, or the harmonization program. At the time we entered into the IMUKIN purchase agreement and the harmonization program commitment was made, we had anticipated achieving certain benefits should the Phase 3 clinical trial evaluating ACTIMMUNE for the treatment of Friedreich’s ataxia, be successful. If the study had been successful and if U.S. marketing approval had subsequently been obtained, we had forecasted significant increases in demand for the medicine and the harmonization program would have resulted in significant benefits for us. Following our discontinuation of the FA program, we determined that certain assets, including an upfront payment related to the IMUKIN purchase agreement, were impaired, and the costs under the harmonization program would no longer have benefit to us and should be expensed as incurred.

 

16.

Represents expenses incurred relating to discontinuation of Friedreich’s ataxia program and a reduction to previous charges recorded.

 

Horizon Therapeutics plc   23